Premium
Meeting report: FDA public meeting on patient‐focused drug development and medication adherence in solid organ transplant patients
Author(s) -
Ettenger Robert,
Albrecht Renata,
Alloway Rita,
Belen Ozlem,
CavailléColl Marc W.,
ChisholmBurns Marie A.,
Dew Mary Amanda,
Fitzsimmons William E.,
Nickerson Peter,
Thompson Graham,
Vaidya Pujita
Publication year - 2018
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14635
Subject(s) - medicine , organ transplantation , transplantation , psychological intervention , intensive care medicine , broad spectrum , family medicine , psychiatry , chemistry , combinatorial chemistry
The Food and Drug Administration ( FDA ) held a public meeting and scientific workshop in September 2016 to obtain perspectives from solid organ transplant recipients, family caregivers, and other patient representatives. The morning sessions focused on the impact of organ transplantation on patients’ daily lives and the spectrum of activities undertaken to maintain grafts. Participants described the physical, emotional, and social impacts of their transplant on daily life. They also discussed their posttransplant treatment regimens, including the most burdensome side effects and their hopes for future treatment. The afternoon scientific session consisted of presentations on prevalence and risk factors for medication nonadherence after transplantation in adults and children, and interventions to manage it. As new modalities of Immunosuppressive Drug Therapy are being developed, the patient perceptions and input must play larger roles if organ transplantation is to be truly successful.